Analysis: Pandemic fatigue makes the case for boosters a harder sell
Some nations are already looking to a fourth vaccine dose to help contend with a huge Omicron-driven spike in COVID-19 cases, but early signs suggest repeat vaccination may be a hard sell as beleaguered populations enter their third pandemic year.
Uber to let office staff work up to half their time from anywhere -source
Uber Technologies Inc (UBER.N) will let employees work half their hours from wherever they want as part of its revamped return-to-office strategy, the transport app company plans to announce on Tuesday, according to a person familiar with the matter.
What you need to know about the coronavirus right now
Here’s what you need to know about the coronavirus right now.
What you need to know about the coronavirus right now
Here’s what you need to know about the coronavirus right now.
U.S. approval of Biogen Alzheimer’s drug sends shares soaring, hailed as ‘big day” for patients
U.S. regulators on Monday approved Biogen Inc’s (BIIB.O) aducanumab as the first treatment to attack a likely cause of Alzheimer’s disease despite controversy over whether the clinical evidence proves the drug works, sending its shares soaring.
AstraZeneca moves finance chief to new role after Alexion deal
AstraZeneca (AZN.L) will move finance chief Marc Dunoyer to head newly acquired rare diseases business Alexion (ALXN.O), using the $39 billion takeover as an opportunity to freshen up a management team that had been in place for eight years.
UK competition regulator looking into $39 bln AstraZeneca-Alexion deal
Britain’s competition regulator is reviewing AstraZeneca’s (AZN.L) $39 billion buyout of U.S.-based Alexion (ALXN.O) on concerns it could reduce competition in the UK market or elsewhere.
